Fig. 4: The bioorthogonal in situ nanomedicine assembly enhanced the anticancer activity of BB94.

a Schematic illustrating the experimental protocol for the orthotopic 4T1 breast tumor model. b Images and H&E staining of collected lung tissues at the end of treatment (n = 5). Scale bar, 0.5 cm. c The number of metastatic lung nodules from mice bearing 4T1 tumors at the end of treatment. Data are presented as the mean ± s.d. (n = 5). Statistical significance was calculated via Student’s t-test (two tail). **p < 0.01, ***p < 0.001; n.s., no significant difference. d Immunoblot analysis of MMP-2, MMP-3, and MMP-9 in primary tumor tissue at the end of treatment. Experiments were repeated twice. e Statistical analysis of the stripe grayscale values in d. f Tumor immunohistochemical staining of MMP-2, MMP-3 and MMP-9 from primary tumor of each group at the end of treatment. Scale bar, 100 µm. A representative image from one of five independent fields of view in a single experiment. i.v.: intravenously, PBS: phosphate buffered saline, MMP: matrix metalloproteinase protease. Source data are provided as a Source Data file.